期刊文献+

骨化三醇治疗慢性肾脏病继发性甲状旁腺功能亢进的疗效 被引量:12

Clinical observation on patients with chronic kidney disease and secondary hyperparathyroidism treated by calcitriol
下载PDF
导出
摘要 目的探讨骨化三醇冲击治疗慢性肾脏病继发性甲状旁腺功能亢进的临床疗效。方法根据血清全段甲状旁腺激素(iPTH)水平选择尚未进入替代治疗的慢性肾脏病(CKD 4、5期)65例,比较治疗前及治疗后4、8、12周的iPTH、血钙、血磷的变化及临床症状的缓解情况。结果 65例患者经治疗12周后,血清iPTH水平明显下降,与治疗前比较差异具有统计学意义(P<0.05)。患者的血钙较治疗前有上升趋势,而血磷有下降趋势。在治疗8、12周时,患者的Ca2+×P3-明显低于治疗前,差异具有统计学意义(P<0.05)。临床症状有不同程度改善,72.3%患者症状明显改善。结论骨化三醇口服治疗慢性肾脏病合并继发性甲状旁腺功能亢进的非透析患者疗效显著,临床症状改善明显。 Objective To evaluate the efficacy of calcitriol on patients with chronic kidney disease and sec-ondary hyperparathyroidism. Methods 65 cases of chronic kidney disease patients who had tentered alternative therapy with elevated intactparathyroid hormone were, the serum concentration of iPTH, change of calcium and phosphorus, the remission degree of clinical symptoms were tested before and at the 4th, 8th and 12th week after calcitriol treatment. Results After 12 week-treatment, the serum iPTH level decreased significantly( P 〈 0. 05 ), the serum calcium had an upward trend and the serum phosphorus concentration had a downward trend. After the treatment for 8 and 12 weeks, the Ca^2+×P^3-was significantly lower( P 〈 0. 05 ). The clinical symptoms had been improved, the clinical effective rate was 72. 3 %. Conclusion Oral calcitriol has obvious effect on patients with secondary hyperparathyroidism without he- modialysis,it is worthy of popularization.
作者 袁移安
出处 《实用药物与临床》 CAS 2013年第6期483-484,共2页 Practical Pharmacy and Clinical Remedies
关键词 慢性肾脏病 继发性甲状旁腺功能亢进 甲状旁腺激素 Chronic kidney disease Secondary hyperparathyroidism Parathyroid hormone
  • 相关文献

参考文献8

二级参考文献78

  • 1杨继红,李天慧,王海涛,陈欢,吴华.活性维生素D和低钙透析液治疗血液透析患者继发性甲状旁腺功能亢进的疗效观察[J].中国血液净化,2006,5(5):242-244. 被引量:19
  • 2黎磊石,刘志红主编.中国肾脏病学[M].北京:人民军医出版社,2008,1328-1338
  • 3洪虹,苗华.骨化三醇联合低钙透析在维持性血液透析老年患者中的应用——附17例报告[J].新医学,2007,38(7):460-461. 被引量:4
  • 4[2]Quarles LD, Indridason OS. Calcitriol administration in end-stage renaldisease: intraverous or oral. Peodiliaty Nephrol, 1996,10(3): 331-336
  • 5[3]Feldman D, Malloy P. Hereditary 1.25-dihydroxy vitamin Dreststant rick-ets: molecular basis and implications for role of 1,25 (OH) 2D 3 in normalPlnysiology. Mol Cell Endocrinol, 1990,72: C57
  • 6[4]Sone T. Auniqme point mutation in the human Vitamin D receptor chromo-somal gene confers hereolitar resistance to 1,25-dihydroxyvitamin D 3.Mol Endocrinol, 1990,14:623
  • 7[5]Rousseau GG, Van Bohemen CE. Effect os membrane-acitive Compoind ondexamethasone binding to The glulocotrticoid receptor in intract cells. JSteroid Biochem, 1984,20:37
  • 8[6]Russell DW. CDNA Cloning of the vovine low density Lipoprotein recep-tor:feedback reguleim of a receptor mRNA. Prol Natl Acad Sci USA,1983,80: 750
  • 9[7]Naveh Many T, Marx R. j rEGULATION OF 1,25-dihydroxy vitamin D 3veceptor gene expression by 1,25-dinyolroxy vitamin D 3 in the parathy-roid in vivo. Clin Invest, 1990,86:1968-1975
  • 10[8]Malberti F,Surian M. Jmprovement of secondary hyperparathyroidism andreduction of set point of calcium after intraverus calcitiol. Coscip KidneyInt, 1993, [ Supple]41: s125

共引文献91

同被引文献113

  • 1俞小敏,肖洁,黄咏璋.血液透析患者继发性甲状旁腺功能亢进与贫血的关系[J].广州医学院学报,2014,42(1):40-42. 被引量:3
  • 2张超,胡昭,董帅.终末期肾病维持性血液透析患者生存率和死亡的影响因素[J].中国老年学杂志,2014,34(5):1241-1243. 被引量:59
  • 3王梅.维持性血液透析患者钙磷代谢紊乱的机制与处理对策[J].中国实用内科杂志,2007,27(22):1747-1749. 被引量:15
  • 4黎磊石,刘志红.中国.肾脏病学:下册[M].北京:人民军医出版社.2008:1077-1094.
  • 5Saliba W,E 1 Haddad B.Secondary hyperparathyroidism:pathophy- siology and treatment[J].J Am Board Faro Med,2009,22(5):574- 581.
  • 6Kidney Disease.Improving Global Outeomes(K/DOQI)CKDMBD Work Group.KfDOQI Clinical Practice Guideline for the Diag nosis,Evaluation,Prevention,and Treatment of Chronic kidney Disease-Mineral and Bone Disorder(CKDMBD)[J].Kidney Int Suppl,2009,113(1):S 1-130.
  • 7Gullroglu KS, Gulleroglu NB. Mineral and bone disease in afri- can renal failure patients[ J]. Nephrourol Mon, 2013,5 (2) :779- 780.
  • 8Zhang Q, Qiu J, Li H, et al. Cyclooxygenase 2 promotes parathy- roid hyperplasia in ESRD[J]. J Am Soc Nephrol, 2011,22(4) : 664-672.
  • 9Krishnaveni GV, Veena SR, Winder NR, et al. Maternal vitamin D status during pregnancy and body composition and cardiovascular risk markers in Indian children: the Mysore Parthenon Study [ J ]. Am J Clin Nutr, 2011,93(3) :628-635.
  • 10Miller G, Davis J, Shatzen E, et al. Cinacalcet HC1 prevents de- velopment of parathyroid gland hyperplasia and reverses established parathyroidgland hyperplasia in a rodent model of CKD[ J]. Neph- rol Dial Transplant, 2012,27(6) :2198-2205.

引证文献12

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部